Teva’s Ajovy significantly reduces migraine in children and adolescents
Esme Needham | January 12, 2026 | News story | Research and Development | Neurology, Teva, ajovy, migraine
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children and adolescents with episodic migraine in new trial results.
Results from the phase 3 SPACE study, published in the New England Journal of Medicine, demonstrated both the efficacy and safety of Ajovy in children and adolescents with episodic migraine. Ajovy is the first and only calcitonin gene-related peptide (CGRP) antagonist treatment approved for prevention of both migraine in adults and episodic migraine in children.
The SPACE study evaluated 237 children and adolescents aged between 6-17 who suffered from episodic migraine. Study data showed that Ajovy reduced monthly migraine days (MMD) by 2.5 days, compared to 1.4 days in the placebo group. It also reduced monthly headache days (MHD) of moderate or worse severity by 2.6 days, compared to 1.5 days in the placebo group. A much higher number of patients in the Ajovy treatment group achieved a >50% reduction in MMD than in the placebo group.
The safety profile of Ajovy in children and adolescents was found to be consistent with its established profile in adults, and no new safety signals were observed.
Migraine is a condition characterised by intense, often debilitating headaches, as well as symptoms such as nausea, vomiting and light and sound sensitivity. For children and adolescents living with migraine, the condition can prevent socialising and learning.
“Helping to prevent migraine attacks in children and adolescents is critical to supporting their healthy development and education, including missed school days, disability and overall social well-being,” said Andrew D Hershey, endowed chair and director of neurology at Cincinnati Children’s Hospital Medical Center and a lead author of the study.
Related Content
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities …
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
